1. Home
  2. TYRA vs DRTS Comparison

TYRA vs DRTS Comparison

Compare TYRA & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

SELL

Current Price

$19.70

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

SELL

Current Price

$12.01

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TYRA
DRTS
Founded
2018
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TYRA
DRTS
Price
$19.70
$12.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
5
Target Price
★ $47.45
$20.60
AVG Volume (30 Days)
★ 577.7K
549.0K
Earning Date
11-10-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,793.58
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.94
$3.43
52 Week High
$40.65
$15.79

Technical Indicators

Market Signals
Indicator
TYRA
DRTS
Relative Strength Index (RSI) 41.01 37.83
Support Level $18.46 $11.49
Resistance Level $22.69 $14.15
Average True Range (ATR) 1.19 0.78
MACD -0.10 -0.11
Stochastic Oscillator 12.33 12.97

Price Performance

Historical Comparison
TYRA
DRTS

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: